Skip to content

Study · Randomized controlled trial · n = 168 · 2023

4 results

Testosterone castration levels in patients with prostate cancer: Is there a difference between GnRH agonist and GnRH antagonist? Primary results of an open-label randomized control study.

Mytilekas VK, Papaefstathiou E, Koukourikis P, Ouzounidis X, Kazantzidis S, Hatzimouratidis K

Investigative and clinical urology1 Nov 2023Cited by 4 (Europe PMC)

PMID37932568 (opens in a new tab)PMCIDPMC10630685 (opens in a new tab)DOI10.4111/icu.20230027 (opens in a new tab)PepBankPUB-37932568
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with prostate cancer, degarelix produced lower testosterone at the first month than GnRH agonist treatment (22 versus 29 ng/dL, p=0.011).

    In plain wordsIn patients with prostate cancer, testosterone was lower with degarelix than with GnRH agonist treatment at the first month.

    Peptide
    Degarelix
    Outcome
    DecreaseTestosterone at first month
    Study

    n = 168

    Comparator
    GnRH agonist
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Testosterone at first month
    22 ng/dL
    Degarelix (group A)
    Testosterone at first month
    29 ng/dL
    GnRH agonist (group B)

    Source sentences

    Summary
    Testosterone levels at 1st month were significantly lower in patients under GnRH antagonist than those receiving GnRH agonist (group A: 22 ng/dL vs. group B: 29 ng/dL, p=0.011).
    1 context sentence
    Summary · context
    Patients with prostate cancer (PCa) of a single outpatient clinic were randomized (2:1) to receive degarelix (group A) or GnRH agonist (group B).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with prostate cancer, PSA did not differ between degarelix and GnRH agonist treatment (0.130 versus 0.067 ng/mL, p=0.261).

    In plain wordsIn patients with prostate cancer, PSA did not differ significantly between degarelix and GnRH agonist treatment.

    Peptide
    Degarelix
    Outcome
    No significant changePSA
    Study

    n = 168

    Comparator
    GnRH agonist
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    PSA
    0.13 ng/mL
    Degarelix (group A)
    PSA
    0.067 ng/mL
    GnRH agonist (group B)

    Source sentences

    Summary
    However, PSA values did not differ significantly between groups (group A: 0.130 ng/mL vs. group B: 0.067 ng/mL, p=0.261).
    1 context sentence
    Summary · context
    Patients with prostate cancer (PCa) of a single outpatient clinic were randomized (2:1) to receive degarelix (group A) or GnRH agonist (group B).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with prostate cancer, degarelix independently predicted lower testosterone at the first month in multivariate analysis (p=0.013).

    In plain wordsIn patients with prostate cancer, adjusted analysis linked degarelix to lower first-month testosterone than GnRH agonist treatment.

    Peptide
    Degarelix
    Outcome
    DecreaseAdjusted testosterone at first month
    Study

    n = 168

    Comparator
    GnRH agonist
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In multivariate analysis, treatment with degarelix was an independent factor of lower testosterone levels at 1st month (p=0.013).
    1 context sentence
    Summary · context
    Patients with prostate cancer (PCa) of a single outpatient clinic were randomized (2:1) to receive degarelix (group A) or GnRH agonist (group B).
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with prostate cancer, testosterone levels at 6, 12, and 18 months showed no significant difference within each group (degarelix or GnRH agonist).

    In plain wordsIn patients with prostate cancer, testosterone showed no significant difference within each group (degarelix or GnRH agonist) at 6, 12 and 18 months.

    Peptide
    Degarelix
    Outcome
    No significant changeTestosterone over later visits
    Study

    n = 168

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Comparison of testosterone levels at 6, 12, and 18 months did not reveal any significant difference within each group.
    2 context sentences
    Summary · context
    The study included 168 patients, 107 in group A and 61 in group B.
    Summary · context
    Patients with prostate cancer (PCa) of a single outpatient clinic were randomized (2:1) to receive degarelix (group A) or GnRH agonist (group B).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.